Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: KYV-101 anti-CD19 CAR-T cell therapy
- drug: Standard lymphodepletion regimen
Eligibility
Inclusion Criteria:
1. Age ≥18 years
2. Clinical diagnosis of SLE according to 2019 European League Against
Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria
3. Biopsy-proven proliferative LN Class III or IV according to 2018 International Society
of Nephrology/Renal Pathology Society (ISN/RPS) criteria
4. Positive anti-nuclear antibody (ANA) (titer ≥1:80 ), anti-dsDNA (≥30 IU/mL on
enzyme-linked immunosorbent assay [ELISA]), or anti-Smith at screening or by
documented medical history
5. Up to date on recommended vaccinations, including against coronavirus disease 2019
(COVID-19)/ severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), per Centers
for Disease Control and Prevention (CDC) or institutional guidelines for immune
compromised individuals
Exclusion Criteria:
1. Rapidly progressive glomerulonephritis; history of or currently active severe central
nervous system (CNS) lupus, including cerebritis, cerebrovascular accident, and
seizures
2. Prior treatment with cellular immunotherapy (CAR-T) or gene therapy product directed
at any target
3. History of allogeneic or autologous stem cell transplant
4. Evidence of active hepatitis B or hepatitis C infection
5. Positive serology for HIV
6. Primary immunodeficiency
7. History of splenectomy
8. History of stroke, seizure, dementia, Parkinson's disease, coordination movement
disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic
disorder investigator considers would increase the risk for the subject
9. Impaired cardiac function or clinically significant cardiac disease
10. Previous or concurrent malignancy with the following exceptions:
1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing
is required prior to screening)
2. In situ carcinoma of the cervix or breast, treated curatively and without
evidence of recurrence for at least 3 years prior to screening
3. A primary malignancy which has been completely resected, or treated, and is in
complete remission for at least 5 years prior to screening
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kamand Shafieha
650-498-3025
I'm interested
Psoriasis Clinical Trials
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: KYV-101 anti-CD19 CAR-T cell therapy
- drug: Standard lymphodepletion regimen
Eligibility
Inclusion Criteria:
1. Age ≥18 years
2. Clinical diagnosis of SLE according to 2019 European League Against
Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria
3. Biopsy-proven proliferative LN Class III or IV according to 2018 International Society
of Nephrology/Renal Pathology Society (ISN/RPS) criteria
4. Positive anti-nuclear antibody (ANA) (titer ≥1:80 ), anti-dsDNA (≥30 IU/mL on
enzyme-linked immunosorbent assay [ELISA]), or anti-Smith at screening or by
documented medical history
5. Up to date on recommended vaccinations, including against coronavirus disease 2019
(COVID-19)/ severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), per Centers
for Disease Control and Prevention (CDC) or institutional guidelines for immune
compromised individuals
Exclusion Criteria:
1. Rapidly progressive glomerulonephritis; history of or currently active severe central
nervous system (CNS) lupus, including cerebritis, cerebrovascular accident, and
seizures
2. Prior treatment with cellular immunotherapy (CAR-T) or gene therapy product directed
at any target
3. History of allogeneic or autologous stem cell transplant
4. Evidence of active hepatitis B or hepatitis C infection
5. Positive serology for HIV
6. Primary immunodeficiency
7. History of splenectomy
8. History of stroke, seizure, dementia, Parkinson's disease, coordination movement
disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic
disorder investigator considers would increase the risk for the subject
9. Impaired cardiac function or clinically significant cardiac disease
10. Previous or concurrent malignancy with the following exceptions:
1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing
is required prior to screening)
2. In situ carcinoma of the cervix or breast, treated curatively and without
evidence of recurrence for at least 3 years prior to screening
3. A primary malignancy which has been completely resected, or treated, and is in
complete remission for at least 5 years prior to screening
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kamand Shafieha
650-498-3025
I'm interested
Dermatology Clinical Trials
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: KYV-101 anti-CD19 CAR-T cell therapy
- drug: Standard lymphodepletion regimen
Eligibility
Inclusion Criteria:
1. Age ≥18 years
2. Clinical diagnosis of SLE according to 2019 European League Against
Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria
3. Biopsy-proven proliferative LN Class III or IV according to 2018 International Society
of Nephrology/Renal Pathology Society (ISN/RPS) criteria
4. Positive anti-nuclear antibody (ANA) (titer ≥1:80 ), anti-dsDNA (≥30 IU/mL on
enzyme-linked immunosorbent assay [ELISA]), or anti-Smith at screening or by
documented medical history
5. Up to date on recommended vaccinations, including against coronavirus disease 2019
(COVID-19)/ severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), per Centers
for Disease Control and Prevention (CDC) or institutional guidelines for immune
compromised individuals
Exclusion Criteria:
1. Rapidly progressive glomerulonephritis; history of or currently active severe central
nervous system (CNS) lupus, including cerebritis, cerebrovascular accident, and
seizures
2. Prior treatment with cellular immunotherapy (CAR-T) or gene therapy product directed
at any target
3. History of allogeneic or autologous stem cell transplant
4. Evidence of active hepatitis B or hepatitis C infection
5. Positive serology for HIV
6. Primary immunodeficiency
7. History of splenectomy
8. History of stroke, seizure, dementia, Parkinson's disease, coordination movement
disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic
disorder investigator considers would increase the risk for the subject
9. Impaired cardiac function or clinically significant cardiac disease
10. Previous or concurrent malignancy with the following exceptions:
1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing
is required prior to screening)
2. In situ carcinoma of the cervix or breast, treated curatively and without
evidence of recurrence for at least 3 years prior to screening
3. A primary malignancy which has been completely resected, or treated, and is in
complete remission for at least 5 years prior to screening
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kamand Shafieha
650-498-3025
I'm interested
Pediatric Dermatology Clinical Trials
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: KYV-101 anti-CD19 CAR-T cell therapy
- drug: Standard lymphodepletion regimen
Eligibility
Inclusion Criteria:
1. Age ≥18 years
2. Clinical diagnosis of SLE according to 2019 European League Against
Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria
3. Biopsy-proven proliferative LN Class III or IV according to 2018 International Society
of Nephrology/Renal Pathology Society (ISN/RPS) criteria
4. Positive anti-nuclear antibody (ANA) (titer ≥1:80 ), anti-dsDNA (≥30 IU/mL on
enzyme-linked immunosorbent assay [ELISA]), or anti-Smith at screening or by
documented medical history
5. Up to date on recommended vaccinations, including against coronavirus disease 2019
(COVID-19)/ severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), per Centers
for Disease Control and Prevention (CDC) or institutional guidelines for immune
compromised individuals
Exclusion Criteria:
1. Rapidly progressive glomerulonephritis; history of or currently active severe central
nervous system (CNS) lupus, including cerebritis, cerebrovascular accident, and
seizures
2. Prior treatment with cellular immunotherapy (CAR-T) or gene therapy product directed
at any target
3. History of allogeneic or autologous stem cell transplant
4. Evidence of active hepatitis B or hepatitis C infection
5. Positive serology for HIV
6. Primary immunodeficiency
7. History of splenectomy
8. History of stroke, seizure, dementia, Parkinson's disease, coordination movement
disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic
disorder investigator considers would increase the risk for the subject
9. Impaired cardiac function or clinically significant cardiac disease
10. Previous or concurrent malignancy with the following exceptions:
1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing
is required prior to screening)
2. In situ carcinoma of the cervix or breast, treated curatively and without
evidence of recurrence for at least 3 years prior to screening
3. A primary malignancy which has been completely resected, or treated, and is in
complete remission for at least 5 years prior to screening
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kamand Shafieha
650-498-3025
I'm interested
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: KYV-101 anti-CD19 CAR-T cell therapy
- drug: Standard lymphodepletion regimen
Eligibility
Inclusion Criteria:
1. Age ≥18 years
2. Clinical diagnosis of SLE according to 2019 European League Against
Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria
3. Biopsy-proven proliferative LN Class III or IV according to 2018 International Society
of Nephrology/Renal Pathology Society (ISN/RPS) criteria
4. Positive anti-nuclear antibody (ANA) (titer ≥1:80 ), anti-dsDNA (≥30 IU/mL on
enzyme-linked immunosorbent assay [ELISA]), or anti-Smith at screening or by
documented medical history
5. Up to date on recommended vaccinations, including against coronavirus disease 2019
(COVID-19)/ severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), per Centers
for Disease Control and Prevention (CDC) or institutional guidelines for immune
compromised individuals
Exclusion Criteria:
1. Rapidly progressive glomerulonephritis; history of or currently active severe central
nervous system (CNS) lupus, including cerebritis, cerebrovascular accident, and
seizures
2. Prior treatment with cellular immunotherapy (CAR-T) or gene therapy product directed
at any target
3. History of allogeneic or autologous stem cell transplant
4. Evidence of active hepatitis B or hepatitis C infection
5. Positive serology for HIV
6. Primary immunodeficiency
7. History of splenectomy
8. History of stroke, seizure, dementia, Parkinson's disease, coordination movement
disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic
disorder investigator considers would increase the risk for the subject
9. Impaired cardiac function or clinically significant cardiac disease
10. Previous or concurrent malignancy with the following exceptions:
1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing
is required prior to screening)
2. In situ carcinoma of the cervix or breast, treated curatively and without
evidence of recurrence for at least 3 years prior to screening
3. A primary malignancy which has been completely resected, or treated, and is in
complete remission for at least 5 years prior to screening
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kamand Shafieha
650-498-3025
I'm interested
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: KYV-101 anti-CD19 CAR-T cell therapy
- drug: Standard lymphodepletion regimen
Eligibility
Inclusion Criteria:
1. Age ≥18 years
2. Clinical diagnosis of SLE according to 2019 European League Against
Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria
3. Biopsy-proven proliferative LN Class III or IV according to 2018 International Society
of Nephrology/Renal Pathology Society (ISN/RPS) criteria
4. Positive anti-nuclear antibody (ANA) (titer ≥1:80 ), anti-dsDNA (≥30 IU/mL on
enzyme-linked immunosorbent assay [ELISA]), or anti-Smith at screening or by
documented medical history
5. Up to date on recommended vaccinations, including against coronavirus disease 2019
(COVID-19)/ severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), per Centers
for Disease Control and Prevention (CDC) or institutional guidelines for immune
compromised individuals
Exclusion Criteria:
1. Rapidly progressive glomerulonephritis; history of or currently active severe central
nervous system (CNS) lupus, including cerebritis, cerebrovascular accident, and
seizures
2. Prior treatment with cellular immunotherapy (CAR-T) or gene therapy product directed
at any target
3. History of allogeneic or autologous stem cell transplant
4. Evidence of active hepatitis B or hepatitis C infection
5. Positive serology for HIV
6. Primary immunodeficiency
7. History of splenectomy
8. History of stroke, seizure, dementia, Parkinson's disease, coordination movement
disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic
disorder investigator considers would increase the risk for the subject
9. Impaired cardiac function or clinically significant cardiac disease
10. Previous or concurrent malignancy with the following exceptions:
1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing
is required prior to screening)
2. In situ carcinoma of the cervix or breast, treated curatively and without
evidence of recurrence for at least 3 years prior to screening
3. A primary malignancy which has been completely resected, or treated, and is in
complete remission for at least 5 years prior to screening
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kamand Shafieha
650-498-3025
I'm interested